Drug intelligence / Profile preview

glycerated phenol

Development stage: Unknown
Lead developer: ALK Abelló
Modality: Small Molecules
Administration: Intradermal, Subcutaneous

Overview

**Glycerated phenol** is a fixed-composition sterile diluent product marketed in Canada as **Glycerinated Phenol Saline** by ALK-Abelló. The registered liquid formulation contains glycerine 50%, sodium chloride 0.9%, and phenol 0.4%, and is classified as an ATC V07AB solvent and diluting agent. It is supplied for intradermal or subcutaneous use as a vehicle for allergenic-extract preparation rather than as a disease-directed pharmacotherapy. ([hpr-rps.hres.ca](https://hpr-rps.hres.ca/details.php?drugproductid=3761))

Brand names: Glycerinated Phenol Saline
Other names: glycerated phenolglycerinated phenolphenol-glycerol

Beyond the preview

Go deeper on glycerated phenol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on glycerated phenol.

Explore the full profile